Detalhe da pesquisa
1.
Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide.
J Biol Chem
; 296: 100807, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34022222
2.
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
J Hepatol
; 73(6): 1322-1332, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32610115
3.
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
J Hepatol
; 72(4): 613-626, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31697972
4.
Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.
Hepatology
; 65(5): 1543-1556, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28027586
5.
The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism.
Exp Physiol
; 102(8): 985-999, 2017 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28597936
6.
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier.
Proc Natl Acad Sci U S A
; 110(14): 5422-7, 2013 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-23513224
8.
Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.
J Biol Chem
; 287(28): 23537-48, 2012 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-22621923
9.
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.
Bioorg Med Chem
; 26(22): 5870-5884, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30429097
10.
Insulin sensitizers in 2023: lessons learned and new avenues for investigation.
Expert Opin Investig Drugs
; 32(9): 803-811, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37755339
11.
Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism.
Mol Metab
; 70: 101694, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36801448
12.
Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19.
Sci Immunol
; 8(82): eadf0348, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821695
13.
Metabolic Mechanisms Connecting Alzheimer's and Parkinson's Diseases: Potential Avenues for Novel Therapeutic Approaches.
Front Mol Biosci
; 9: 929328, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35782864
14.
The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease.
Mol Metab
; 55: 101409, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34863942
15.
Re-routing Metabolism by the Mitochondrial Pyruvate Carrier Inhibitor MSDC-0160 Attenuates Neurodegeneration in a Rat Model of Parkinson's Disease.
Mol Neurobiol
; 59(10): 6170-6182, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35895232
16.
Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficits.
Free Neuropathol
; 12020.
Artigo
em Inglês
| MEDLINE | ID: mdl-35224554
17.
MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis.
Expert Opin Investig Drugs
; 27(7): 631-636, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29950116
18.
Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat.
Diab Vasc Dis Res
; 4(2): 117-23, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17654445
19.
Treating fatty liver disease by modulating mitochondrial pyruvate metabolism.
Hepatol Commun
; 1(3): 193-197, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29404453
20.
Insulin sensitizers may prevent metabolic inflammation.
Biochem Pharmacol
; 72(2): 125-31, 2006 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-16472781